Avita Medical earnings date
Want to see RCEL full AI Analyst Report?
Avita Medical (RCEL) Q3 2026 Earnings Report
RCEL Q3 2026 EPS Results
- Actual EPS
- -$0.20
- Consensus EPS
- -$0.24
- Beat/Miss
- Beat by +$0.04
- One Year Ago EPS
- -$0.46
RCEL Q3 2026 Revenue Results
- Actual Revenue
- $26.11M
- Expected Revenue
- $22.35M
- Beat/Miss
- Beat by +$3.76M
- YoY Revenue Growth
- +53.05%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
Avita Medical's next earnings date is estimated for February 25, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive. Revenue growth accelerated, RECELL adoption expanded, Cohealyx grew, PermeaDerm produced favorable clinical and economic results, gross margin improved, cash use declined substantially, liquidity strengthened through the additional $10 million credit-facility draw, and full-year guidance was raised for the second consecutive quarter. The main challenges were flat international RECELL and PermeaDerm revenue, continued net losses, lower margins for newer products, ongoing hospital adoption reviews, and some uncertainty around seasonal Q3 volume; these issues were outweighed by the reported operating and financial improvements.
AVITA raised full-year 2026 revenue guidance to $92 million-$94 million from $86 million-$89 million, representing approximately 28%-31% growth over 2025, with $93 million at the midpoint, compared with approximately $35 million in 2022 and a compound annual growth rate of approximately 28% over four years; the guidance implies Q4 revenue of approximately $24.9 million-$26.9 million and approximately 30% growth for the full year over 2025, while the company remains on track to achieve cash flow breakeven in the fourth quarter. RECELL gross margin is currently expected to remain between 85% and 90% over the coming quarters. For 2027, management is not providing formal guidance but said it expects to grow at a rate that it has been growing, keep operating expenses flat, and does not see headcount going up significantly, with commissions having some variability as revenue goes up.
- Strong Third-Quarter Revenue GrowthThird-quarter revenue reached $26.1 million, up 53% year-over-year from $17.1 million and 20% from the second quarter. Revenue for the first nine months of 2026 was approximately $67.1 million.
- Revenue Guidance Raised AgainAVITA raised full-year 2026 revenue guidance for the second consecutive quarter to $92 million-$94 million, compared with the previous range of $86 million-$89 million. The new range represents approximately 28%-31% growth over 2025.
- Reduced Cash Use and Progress Toward BreakevenNet cash use declined to approximately $600,000 in Q3 from $3.2 million in Q2 and $9.9 million in Q1. Management reaffirmed its expectation of achieving cash flow breakeven in the fourth quarter.
- RECELL Revenue and Volume ExpansionU.S. RECELL revenue reached $22.4 million, approximately 20% above Q2. U.S. RECELL volume increased approximately 21% sequentially to 3,196 units, following an increase of more than 11% in Q2 over Q1. Management attributed the growth to higher procedure volumes and increased ordering across accounts.
- RECELL Platform Expansion and Clinical AdoptionRECELL GO and RECELL GO mini provide options for different wound sizes, with mini extending the platform into smaller wounds and RECELL GO supporting larger treatment areas. Management reported continued growth within accounts, including more physicians, procedures, and eligible wound types.
- Growing RECELL Clinical EvidenceA systematic review published in October examined 99 studies across 13 countries and more than two decades of experience with skin cell suspension autografting. All six comparative studies assessing donor skin requirements reported reductions, while the 18 studies evaluating healing reported either favorable or comparable outcomes.
- Positive Medicare Reimbursement UpdateCMS issued its final rule establishing national relative value units for physicians performing procedures using RECELL under the Medicare Physician Fee Schedule. The new category 1 CPT code family is scheduled to take effect on January 1, 2027, simplifying the current structure from eight codes to four based on wound size and anatomic location.
- Cohealyx Revenue Growth and Clinical EvidenceCohealyx revenue reached $2.1 million, up approximately 21% from Q2. The interim Cohealyx I study reported a median time to graft readiness of approximately 11 days, with some patients ready within the first week. Complete six-month follow-up data was expected during the month of the call.
- PermeaDerm Clinical and Economic ResultsThe randomized PermeaDerm I study met its primary endpoint in 40 patients across 11 U.S. burn centers. PermeaDerm demonstrated a 70% economic advantage over allograft, reduced preparation time by approximately 96%, and produced comparable graft take and wound-healing outcomes. Approximately 94% of PermeaDerm patients achieved at least 95% graft take one week after autografting, and all patients in both groups were healed by eight weeks.
- Portfolio Cross-Selling OpportunityManagement described a portfolio in which PermeaDerm protects and stabilizes the wound, Cohealyx rebuilds the wound bed, and RECELL restores the patient's skin. Depending on the patient and wound, one, two, or three products may be used, creating opportunities to address multiple stages of care within the same account.
- Strong Clinical and Conference EngagementAcross four American Burn Association regional conferences this year, 26 presentations involved AVITA technologies, including RECELL outcomes in pediatric, geriatric, and complex burn populations, facial and hand reconstruction, limb salvage, and presentations involving two or more AVITA products.
- Improved Gross Margin and Operating LeverageGross margin increased to 84%, compared with 81.3% in the prior-year quarter and 81.9% in Q2, a 270-basis-point improvement versus the prior-year quarter. Gross profit was approximately $21.9 million, up approximately $4.2 million from Q2. Operating expenses were $24.6 million, flat sequentially despite the 20% revenue increase.
- RECELL Gross Margin StrengthRECELL gross margin reached 88.4%, and management currently expects it to remain between 85% and 90% over the coming quarters.
- Additional Liquidity and Removal of Going-Concern QualificationAVITA satisfied the $85 million trailing 12-month net revenue milestone required to draw the remaining $10 million under its Perceptive Advisors credit facility and received the funds during the week of the call. Management concluded, with auditor concurrence, that substantial doubt about the company's ability to continue as a going concern had been alleviated; the Q3 Form 10-Q no longer includes that qualification, and outstanding debt was classified as long-term.
- Rapid Response to Alberta Burn InjuriesFollowing the fire at Wainwright Military Base in Alberta, Canada, AVITA donated about three dozen RECELL units to burn centers in Calgary and Edmonton, sent staff to train and support clinical teams, and reported that the first patient received treatment within days. Health Canada facilitated access even though RECELL is not commercially available in Canada.
- International RECELL ExpansionAVITA continued building experience with RECELL GO in markets with regulatory authorization, including the first RECELL GO cases in Australia.
- Expected Cost Discipline in 2027Management said it does not expect headcount to increase significantly in 2027 and intends to maintain operating costs at approximately the current level while growing revenue. It also expects first-quarter 2027 cash use for benefit resets and incentive compensation payments, with commissions varying as sales increase.
RCEL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 25, 2027 | 2026 (Q4) | -0.15- | -0.38 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.24-0.20 | -0.46 | 56.52% (+0.26) | |
| Aug 06, 2026 | 2026 (Q2) | -0.29-0.25 | -0.38 | 34.21% (+0.13) | |
| May 14, 2026 | 2026 (Q1) | -0.29-0.35 | -0.53 | 33.96% (+0.18) | |
| Feb 12, 2026 | 2025 (Q4) | -0.36-0.38 | -0.44 | 13.64% (+0.06) | |
| Nov 06, 2025 | 2025 (Q3) | -0.33-0.46 | -0.62 | 25.81% (+0.16) | |
| Aug 07, 2025 | 2025 (Q2) | -0.25-0.38 | -0.6 | 36.67% (+0.22) | |
| May 08, 2025 | 2025 (Q1) | -0.32-0.53 | -0.73 | 27.40% (+0.20) | |
| Feb 13, 2025 | 2024 (Q4) | -0.45-0.44 | -0.28 | -57.14% (-0.16) | |
| Nov 07, 2024 | 2024 (Q3) | -0.45-0.62 | -0.34 | -82.35% (-0.28) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


